Literature DB >> 32124414

Contraceptive technologies for global health: ethically getting to safe, effective and acceptable options for women and men.

John Townsend1, Régine Sitruk-Ware2, Saumya RamaRao2, Jim Sailer2.   

Abstract

While the contributions of science, biomedicine, and engineering to contraceptive development offer wonder and promise to the community, what inspires many of us in the not-for-profit sector about the process of contraceptive product development is the integration of consultations with users, providers and policy makers, good clinical and manufacturing practice in product design and development, and the delivery of approved products at affordable prices to those in greatest need. The commitment to have an impact on the reproductive lives of women and men along with the ethical principles embedded in this process of achieving safe, effective, and acceptable options include the respect for persons, i.e., eventual users, beneficence for those using the product and justice in ensuring that it is available to those who are most vulnerable, including those in developing countries. It is the inspiration that drives the scientists and developers to produce public benefit and additional social value.

Entities:  

Keywords:  Beneficence; Client needs; Contraceptives; Product development and introduction; Reproductive justice; Respect

Year:  2020        PMID: 32124414     DOI: 10.1007/s13346-020-00726-3

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  2 in total

1.  Addressing contraceptive needs exacerbated by COVID-19: A call for increasing choice and access to self-managed methods.

Authors:  Lisa B Haddad; Saumya RamaRao; Avishek Hazra; Harriet Birungi; Jim Sailer
Journal:  Contraception       Date:  2021-03-27       Impact factor: 3.375

2.  Contraceptive Technologies: Looking Ahead to New Approaches to Increase Options for Family Planning.

Authors:  Lisa B Haddad; John W Townsend; Regine Sitruk-Ware
Journal:  Clin Obstet Gynecol       Date:  2021-09-01       Impact factor: 1.966

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.